These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34703834)

  • 1. Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan.
    Matsumoto T; Darlington O; Miller R; Gordon J; McEwan P; Ohashi T; Taie A; Yuasa A
    J Health Econ Outcomes Res; 2021; 8(2):64-75. PubMed ID: 34703834
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia.
    Gordon JP; Al Taie A; Miller RL; Dennis JW; Blaskovich MAT; Iredell JR; Turnidge JD; Coombs GW; Grolman DC; Youssef J
    Infect Dis Ther; 2023 Jul; 12(7):1875-1889. PubMed ID: 37341866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece.
    Barmpouni M; Gordon JP; Miller RL; Dennis JW; Grammelis V; Rousakis A; Souliotis K; Poulakou G; Daikos GL; Al-Taie A
    Infect Dis Ther; 2023 Jul; 12(7):1891-1905. PubMed ID: 37410343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study.
    Matsumoto T; Yuasa A; Miller R; Pritchard C; Ohashi T; Taie A; Gordon J
    Pharmacoecon Open; 2023 Jan; 7(1):65-76. PubMed ID: 36107306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Clinical and Economic Impact of Introducing a New Antibacterial into Greek Clinical Practice for the Management of Hospital-Acquired Infections with Limited Treatment Options.
    Barmpouni M; Gordon JP; Miller RL; Pritchard CRJ; Dennis JW; Grammelis V; Rousakis A; Souliotis K; Poulakou G; Daikos GL; Al-Taie A
    Infect Dis Ther; 2023 Feb; 12(2):527-543. PubMed ID: 36544074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model.
    Gordon J; Darlington O; McEwan P; Lumley M; Taie A; Hicks M; Charbonneau C; Blake A; Hawkins N; Goldenberg S; Otter J; Wilcox M
    Pharmacoeconomics; 2020 Aug; 38(8):857-869. PubMed ID: 32249396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use.
    Shrestha P; Cooper BS; Coast J; Oppong R; Do Thi Thuy N; Phodha T; Celhay O; Guerin PJ; Wertheim H; Lubell Y
    Antimicrob Resist Infect Control; 2018; 7():98. PubMed ID: 30116525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia.
    Wozniak TM; Dyda A; Merlo G; Hall L
    Lancet Reg Health West Pac; 2022 Oct; 27():100521. PubMed ID: 35832237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Road to comprehensive estimation of antimicrobial resistance (AMR) disease burden in Japan.
    Tsuzuki S; Matsunaga N; Ohmagari N
    Glob Health Med; 2020 Jun; 2(3):164-167. PubMed ID: 33330801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan.
    Tsuzuki S; Koizumi R; Matsunaga N; Ohmagari N
    Infect Dis Ther; 2023 Jul; 12(7):1823-1834. PubMed ID: 37318709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.
    Ohashi T; Nagashima M; Kawai N; Ohmagari N; Tateda K
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1603-1614. PubMed ID: 36368311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of the World Health Organization Global Antimicrobial Resistance Surveillance System in Uganda, 2015-2020: Mixed-Methods Study Using National Surveillance Data.
    Nabadda S; Kakooza F; Kiggundu R; Walwema R; Bazira J; Mayito J; Mugerwa I; Sekamatte M; Kambugu A; Lamorde M; Kajumbula H; Mwebasa H
    JMIR Public Health Surveill; 2021 Oct; 7(10):e29954. PubMed ID: 34673531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens.
    Abdeta A; Bitew A; Fentaw S; Tsige E; Assefa D; Lejisa T; Kefyalew Y; Tigabu E; Evans M
    PLoS One; 2021; 16(12):e0256556. PubMed ID: 34855767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excess annual economic burdens from nosocomial infections caused by multi-drug resistant bacteria in Thailand.
    Phodha T; Riewpaiboon A; Malathum K; Coyte PC
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):305-312. PubMed ID: 30321493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial Resistance.
    Marston HD; Dixon DM; Knisely JM; Palmore TN; Fauci AS
    JAMA; 2016 Sep; 316(11):1193-1204. PubMed ID: 27654605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study.
    Gordon J; Gheorghe M; Harrison C; Miller R; Dennis J; Steuten L; Goldenberg S; Gandra S; Al-Taie A
    Pharmacoeconomics; 2024 Mar; 42(3):329-341. PubMed ID: 38001394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?
    Kariuki S; Kering K; Wairimu C; Onsare R; Mbae C
    Infect Drug Resist; 2022; 15():3589-3609. PubMed ID: 35837538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Surveillance of Antimicrobial Resistance among Gram-Negative Bacteria Isolated from Bloodstream Infections in Ghana.
    Donkor ES; Muhsen K; Johnson SAM; Kotey FCN; Dayie NTKD; Tetteh-Quarcoo PB; Tette EMA; Osei MM; Egyir B; Nii-Trebi NI; Owusu-Okyere G; Owusu-Ofori A; Amir Y; Perlman S; Lopes PH; Mfodwo A; Gordon NC; Gresham L; Smolinski M; Cohen D
    Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Economic Evaluation Estimating the Clinical and Economic Burden of Increased Vancomycin-Resistant Enterococcus faecium Infection Incidence in Japan.
    Sugai M; Yuasa A; Miller RL; Vasilopoulos V; Kurosu H; Taie A; Gordon JP; Matsumoto T
    Infect Dis Ther; 2023 Jun; 12(6):1695-1713. PubMed ID: 37302137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis.
    Langford BJ; Soucy JR; Leung V; So M; Kwan ATH; Portnoff JS; Bertagnolio S; Raybardhan S; MacFadden DR; Daneman N
    Clin Microbiol Infect; 2023 Mar; 29(3):302-309. PubMed ID: 36509377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.